Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians.

Sarcoma

Victorian Adolescent & Young Adult Cancer Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Children's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia.

Published: February 2017


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

. After treatment, bone sarcoma patients carry a high chance of relapse and late effects from multimodal therapy. We hypothesize that significant variation in surveillance practice exists between pediatric medical oncology (PO) and nonpediatric medical oncology (NP) sarcoma disciplines. . Australian sarcoma clinicians were approached to do a web based survey that assessed radiologic surveillance (RS) strategies, late toxicity assessment, and posttreatment psychosocial interventions. In total, 51 clinicians responded. No differences were identified in local disease RS. In metastatic disease response assessment, 100% of POs (23/23) and 93% of NPs (24/26) conducted CT chest. However, this was more likely to occur for NPs in the context of a CT chest/abdomen/pelvis (NP: 10/26; PO: 1/23; = 0.006). POs were more likely to use CXR for RS ( = 0.006). POs showed more prescriptive intensity in assessment of heart function ( = 0.001), hearing ( < 0.001), and fertility ( = 0.02). POs were more likely to deliver written information for health maintenance/treatment summary ( = 0.04). The majority of respondents described enquiring about psychosocial aspects of health ( = 33/37, 89%), but a routine formal psychosocial screen was only used by 23% ( = 6/26). . There is high variability in bone sarcoma surveillance between PO and NP clinicians. Efforts to harmonize approaches would allow early and late effects recognition/intervention and facilitate improved patient care/transition and research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350324PMC
http://dx.doi.org/10.1155/2017/1837475DOI Listing

Publication Analysis

Top Keywords

bone sarcoma
12
surveillance practice
8
australian sarcoma
8
sarcoma clinicians
8
late effects
8
medical oncology
8
0006 pos
8
sarcoma
6
variations surveillance
4
practice patients
4

Similar Publications

Diagnosis, management and the burden of symptoms of mastocytosis from the physician's perspective: A nationwide study.

Br J Haematol

September 2025

Platform of Molecular Analysis for Mastocytosis and MCAD (CEREMAST), Department of Biological Hematology, Pitié-Salpêtrière Hospital, AP-HP, Paris Sorbonne University, Paris, France.

Mastocytosis is categorized into cutaneous mastocytosis (CM), mast cell sarcoma and systemic mastocytosis (SM). Within SM, indolent SM (ISM) is the more frequent subtype. Adult patients with CM but without an extracutaneous biopsy are classified as having mastocytosis in the skin (MIS), a provisional diagnosis.

View Article and Find Full Text PDF

Clinicopathological features of dermal clear cell sarcoma: A series of 13 cases.

Pathol Res Pract

September 2025

Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China. Electronic address:

Background: Dermal clear cell sarcoma (DCCS) is a rare malignant mesenchymal neoplasm. Owing to the overlaps in its morphological and immunophenotypic profiles with a broad spectrum of tumors exhibiting melanocytic differentiation, it is frequently misdiagnosed as other tumor entities in clinical practice. By systematically analyzing the clinicopathological characteristics, immunophenotypic features, and molecular biological properties of DCCS, this study intends to further enhance pathologists' understanding of this disease and provide a valuable reference for its accurate diagnosis.

View Article and Find Full Text PDF

Indocyanine green (ICG) is a well-established near-infrared dye which has been used clinically for several decades. Recently, it has been utilised for fluorescence-guided surgery in a range of solid cancer types, including sarcoma, with the aim of reducing the positive margin rate. The increased uptake and retention of ICG within tumours, compared with normal tissue, gives surgeons a visual reference to aid resection when viewed through a near-infrared camera.

View Article and Find Full Text PDF

The combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas has been proposed owing to the enhanced effect of antiangiogenic therapies on the tumor microenvironment. We found eight studies published to date assessing the effectiveness of combined multitargeted vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitors with immune checkpoint inhibitors (ICIs) in sarcoma. It is difficult to draw conclusions owing to limited data and primarily single-arm studies, although initial literature appears promising and requires further study.

View Article and Find Full Text PDF

Metastatic renal osteosarcoma is a rare entity. We report a case of a 52-year-old male postright nephrectomy status presented to us with metastatic renal osteosarcoma. 18-fluorine- fluorodeoxyglucose (F-FDG) avid lesions were seen in the right renal bed with extension to adjacent hepatic parenchyma.

View Article and Find Full Text PDF